Patents Assigned to Matrix Laboratories Ltd.
  • Patent number: 8247568
    Abstract: The present invention relates to a process for the preparation of pure Rabeprazole sulfoxide using the solvent mixture for the extraction steps and this invention further relates to the process for the preparation of amorphous Rabeprazole sodium using pure rabeprazole base in presence of aqueous NaOH and water miscible solvent and adding an anti-solvent.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: August 21, 2012
    Assignee: Matrix Laboratories Ltd
    Inventors: Om Dutt Tyagi, Purna Chandra Ray, Madhuresh Kumar Sethi, Bhausaheb Chavhan
  • Patent number: 8058453
    Abstract: A cost-effective, industrially feasible process for the manufacture of crystalline Carvedilol Form-II using novel Carvedilol salts comprises the steps of reacting 4-(2,3-epoxy propoxy)carbazole (II) with 2-(2-methoxy phenoxy)ethyl amine (III) followed by acidification with mineral acid in presence of an organic solvent to yield acid addition salts, treatment of the said salts with base(s) in presence of organic solvent(s), water and isolation from the organic solvent(s) followed by crystallization from ethyl acetate.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: November 15, 2011
    Assignee: Matrix Laboratories Ltd.
    Inventors: Gorantla Seeta Ramanjaneyulu, Indukuri Venkata Sunil Kumar, Ketavarapu Narasimha Rao, Jammula Vera Venkata Krishna Kishore
  • Patent number: 8048904
    Abstract: The present invention provides a process for the preparation of Olmesartan medoxomil by condensing the ethyl 4-(1-hydroxy-1-methylethyl)-2-propylimidazole-5-carboxylate with 4-[2-(trityl tetrazol-5-yl)phenyl]benzyl bromide to obtain ethyl 4-(1-hydroxy-1-methyl ethyl)-2-propyl-1-{4-[2-(trityl tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate and then hydrolyzing ethyl 4-(1-hydroxy-1-methyl ethyl)-2-propyl-1-{4-[2-(trityl tetrazol-5-yl)phenyl]phenyl}methyl imidazole-5-carboxylate to obtain trityl Olmesartan dihydrate followed by reacting trityl Olmesartan dihydrate with 4-chloromethyl-5-methyl-2-oxo-1,3-dioxolene to obtain trityl Olmesartan medoxomil and then deprotecting trityl Olmesartan medoxomil to obtain Olmesartan medoxomil.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: November 1, 2011
    Assignee: Matrix Laboratories Ltd.
    Inventors: Gorantla Seeta Ramanjaneyulu, Bandari Mohan, Purna Chandra Ray, Madhuresh Kumar Sethi, Vijendra Singh Rawat, Yerramalla Raja Krishna, Vemula Lakshminarayana, Mamidi Srinivas
  • Patent number: 8049009
    Abstract: The present invention relates to novel Tenofovir disoproxil hemifumarate salt, which is prepared by dealkylation of Phosphonate esters by using mineral acids followed by esterification and crystallization to give crystalline Tenofovir disoproxil. The Tenofovir disoproxil is further converted to fumarate salts with improved yield.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: November 1, 2011
    Assignee: Matrix Laboratories Ltd.
    Inventors: Uma Maheswer Rao Vasireddy, Siva Rama Prasad Vellanki, Raja Babu Balusu, Naga Durga Rao Bandi, Pavan Kumar Jujjavarapu, Sambasiva Rao Ginjupalli, Rama Krishna Pilli
  • Patent number: 8026356
    Abstract: The present invention provides a method for preparing pure Stavudine having purity more than 99.5% comprises: i) Converting 3?,5?-anhydrothymidine to crude Stavudine, ii) Converting crude Stavudine to stable solvates of Stavudine, iii) Desolvation of the solvates to give pure Stavudine. The present invention also disclosed novel solvates of Stavudine and conversion of novel Stavudine solvates to Stavudine.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: September 27, 2011
    Assignee: Matrix Laboratories, Ltd.
    Inventors: Purna Chandra Ray, Jagan Mohana Chary Tummanapalli, Seeta Ramanjaneyulu Gorantla
  • Patent number: 7985759
    Abstract: The present invention relates to novel compounds representated by formula (I), where R, R1, R2, R3, X, Y, m, n are as defined. The present invention relates to compounds of the general formula I their derivatives, their analogs, their tautomeric forms, their stereoisomers, their diastereomers, their bioisosteres, their polymorphs, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them which are predominantly dipeptidyl peptidase IV inhibitors. The present invention also relates to the processes for the preparation of novel compounds of formula (I) and their use in treating type II diabetes and diabetic complications thereof and also for treating dislipidemia, hypercholesterolemia, obesity and hyperglycemia.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: July 26, 2011
    Assignee: Matrix Laboratories Ltd.
    Inventors: Gopalan Balasubramanian, Ravi Dhamjewar, Rasheed Mohammed, Sreedhara Swamy Keshavapura Hosamane, Ishtiyaque Ahmad
  • Patent number: 7943780
    Abstract: The invention relates to process for the preparation of Candesartan cilexetil. More particularly, it relates to the preparation of pure candesartan cilexetil by the deprotection of Trityl candesartan cilexetil with inorganic acids.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: May 17, 2011
    Assignee: Matrix Laboratories Ltd.
    Inventors: Seeta Ramajaneyulu Gorantla, Mohan Bandari, Nageswara Rao Karusala
  • Patent number: 7781585
    Abstract: The present invention relates to a process for purification of novel polymorphic form of Gatifloxacin which comprises dissolving Gatifloxacin in about 15-50 volumes of methanol, removing insolubles if any, adding organic base to the solution, maintaining the solution at temperature of 30° C. to 70° C., for about 20 min to 4 hrs, followed by gradual cooling and maintaining the reaction mass to ?10 to 20° C. for about 1-4 hrs, isolation and drying at temperature of about 45° C. to 65° C.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: August 24, 2010
    Assignee: Matrix Laboratories Ltd
    Inventors: Chava Satyanarayana, Gorantla Seeta Ramanjaneyulu, Indukuri Venkata Sunil Kumar
  • Publication number: 20090253932
    Abstract: The present invention relates to novel chiral resolving agents and a process for resolution of racemic organic acids and their derivatives of the formula (+, ?)—R1R2CHCOOR3 with Cis-(1S,4S)-4[3,4-dichlorophenyl]-1,2,3,4-tetrahydro-N-methyl-1-naphthaloneamine and its Cis-(1R,4R)-isomer as well as Trans-(1S,4R)-4[3,4-dichlorophenyl]-1,2,3,4-tetrahydro-N-methyl-1-naphthaloneamine and its Trans-(1R,4S)-isomer.
    Type: Application
    Filed: July 28, 2005
    Publication date: October 8, 2009
    Applicant: Matrix Laboratories Ltd
    Inventors: Chava Satyanarayana, Bandari Mohan, Madhuresh Kumar Sethl
  • Patent number: 7468442
    Abstract: The present invention provides a cost-effective, industrially feasible process for the manufacture of crystalline Carvedilol Form-II using novel Carvedilol salts comprising a step of reacting 4-(2,3-epoxy propoxy)carbazole (II) with 2-(2-methoxy phenoxy)ethyl amine (III) followed by acidification with mineral acid in presence of an organic solvent to yield acid addition salts, treatment of the said salts with base(s) in presence of organic solvent(s), water and isolation from the organic solvent(s) followed by crystallization from ethyl acetate.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: December 23, 2008
    Assignee: Matrix Laboratories Ltd.
    Inventors: Gorantla Seeta Ramanjaneyulu, Indukuri Venkata Sunil Kumar, Ketavarapu Narasimha Rao, Jammula Vera Venkata Krishna Kishore
  • Patent number: 7439387
    Abstract: The present invention relates to a new industrial feasible process for the preparation of Gabapentin Form-II via a novel intermediate Gabapentin hemisulphate hemihydrate with out forming Gabapentin Form-III by neutralizing the Gabapentin hemisulphate hemihydrate solution with a base at higher temperatures followed by cooling to yield Gabapentin Form II with sulphate ions less than 100 ppm with respect to Gabapentin.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: October 21, 2008
    Assignee: Matrix Laboratories Ltd.
    Inventors: Chava Satyanarayana, Gorantla Seeta Ramanjaneyulu, Indukuri Venkata Sunil Kumar
  • Publication number: 20080146809
    Abstract: A process for the preparation of novel amorphous montelukast sodium by dissolving montelukast free acid in an organic solvent, converting into its alkali salt followed by vacuum drying or spray drying the solution. Alternatively by dissolution of montelukast sodium in organic solvent followed by vacuum drying or spray drying the solution.
    Type: Application
    Filed: November 11, 2005
    Publication date: June 19, 2008
    Applicant: Matrix Laboratories Ltd
    Inventors: Chava Satyanarayana, Gorantla Seeta Ramanjaneyulu, Indukuri Venkata Sunil Kumar